Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SARTORIUS STED BIO    DIM   FR0000053266

SARTORIUS STED BIO

 (DIM)

155
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

SARTORIUS STED BIO : Sartorius Stedim Biotech: Q1 2012 Results

04/24/2012| 05:55am US/Eastern
Recommend:
0

Regulatory News:

The Sartorius Stedim Biotech Group's (Paris:DIM) Investor Relations Release on the Q1 2012 results is now available at www.sartorius.com.

It contains the following information:

- Business development for the first three months and the 2012 forecast

for the Sartorius Stedim Biotech Group

- Consolidated financial statements for the period ended March 31, 2012

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions."

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 2,850 people, and in 2011 earned sales revenue of 477.3 million euros.

Sartorius Corporate Administration GmbH
Petra Kirchhoff, Vice President of Corporate Communications and Investor Relations
Phone: +49(0)551/ 308-1686
Fax: +49(0)551/ 308-3410
E-mail: petra.kirchhoff@sartorius.com
or
Andreas Theisen, Director Investor Relations
Phone: +49(0)551/ 308-1668
Fax: +49(0)551/ 308-1654
E-mail: andreas.theisen(at)sartorius.com
http://www.sartorius.com/en/company/investor-relations


© Business Wire 2012
Recommend :
0
Partner Area
React to this article
 
Latest news on SARTORIUS STED BIO
04/23 SARTORIUS STED BIO: Sartorius Stedim Biotech S.A.: Investor Relations News on t..
04/18SARTORIUS STEDIM BIOTECH SA: quaterly earnings release
04/16 SARTORIUS STED BIO: ex-dividend day for annual dividend
04/15 SARTORIUS STED BIO: Sartorius Stedim Biotech: Fact Sheet on New Reporting Forma..
02/28 SARTORIUS STED BIO: Dividend Proposal by the Board of Directors
02/28 SARTORIUS STED BIO: Sartorius Stedim Biotech S.A.: Dividend Proposal by the Boa..
02/27 SARTORIUS STED BIO: Sartorius Stedim Biotech expands PAT portfolio by adding se..
02/11 SARTORIUS STED BIO: Sartorius Stedim Biotech S.A.: Declaration Relative to the ..
02/04 SARTORIUS STED BIO: Sartorius Stedim Biotech:
01/29 SARTORIUS STED BIO: Successful Fiscal 2012 - New Highs in Sales Revenue and Ear..
Advertisement
Chart
Duration : Period :
SARTORIUS STED BIO Technical Analysis Chart | DIM | FR0000053266 | 4-Traders
Income Statement Evolution
SARTORIUS STED BIO : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.